

## REFERENCE LIST

1. Avillach P, Coloma PM, Gini R, Schuemie M, Mouglin F, Dufour JC, et al. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. *J Am Med Inform Assoc.* 2013 Jan 1;20(1):184-92.
2. Coloma PM, Avillach P, Salvo F, Schuemie MJ, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. *Drug Saf.* 2013 Jan;36(1):13-23.
3. Coloma PM, Trifiro G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage? *Pharmacoepidemiol Drug Saf.* 2012 Jun;21(6):611-21.
4. Defalco FJ, Ryan PB, Soledad Cepeda M. Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. *Health services & outcomes research methodology.* 2013 Mar;13(1):58-67.
5. Duke J, Friedlin J, Li X. Consistency in the safety labeling of bioequivalent medications. *Pharmacoepidem Drug Safe.* 2013;22:294-301.
6. Duke J, Friedlin J, Ryan P. A quantitative analysis of adverse events and "overwarning" in drug labeling. *Archives of internal medicine.* 2011 May 23;171(10):944-6.
7. DuMouchel W, Ryan P, Schuemie M, Madigan D. Evaluation of Disproportionality Safety Signaling Applied to Healthcare Databases. *Drug Safety.* 2013 2013/10/01;36(1):123-32.
8. Evans SJW. Moving Along the Yellow Brick (Card) Road? *Drug Safety.* 2013 2013/10/01;36(1):3-4.
9. Fox BI, Hollingsworth JC, Gray MD, Hollingsworth ML, Gao J, Hansen RA. Developing an expert panel process to refine health outcome definitions in observational data. *J Biomed Inform.* 2013 Oct;46(5):795-804.
10. Hansen RA, Gray MD, Fox BI, Hollingsworth JC, Gao J, Hollingsworth ML, et al. Expert panel assessment of acute liver injury identification in observational data. *Res Social Adm Pharm.* 2013 Jun 7.
11. Hansen RA, Gray MD, Fox BI, Hollingsworth JC, Gao J, Zeng P. How Well Do Various Health Outcome Definitions Identify Appropriate Cases in Observational Studies? *Drug Safety.* 2013 2013/10/01;36(1):27-32.

## REFERENCE LIST

12. Harpaz R, DuMouchel W, LePendou P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. *Clinical pharmacology and therapeutics*. 2013 Jun;93(6):539-46.
13. Harpaz R, DuMouchel W, LePendou P, Bauer-Mehren A, Ryan P, Shah NH. Response to "Logistic regression in signal detection: another piece added to the puzzle". *Clinical pharmacology and therapeutics*. 2013 Sep;94(3):313.
14. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. *Clinical pharmacology and therapeutics*. 2012 Jun;91(6):1010-21.
15. Hartzema AG, Reich CG, Ryan PB, Stang PE, Madigan D, Welebob E, et al. Managing Data Quality for a Drug Safety Surveillance System. *Drug Safety*. 2013 2013/10/01;36(1):49-58.
16. Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. *Med Care*. 2012 Jul;50 Suppl:S60-7.
17. Kahn MG, Raebel MA, Glanz JM, Riedlinger K, Steiner JF. A pragmatic framework for single-site and multisite data quality assessment in electronic health record-based clinical research. *Med Care*. 2012 Jul;50 Suppl:S21-9.
18. Katz AJ, Ryan PB, Racoosin JA, Stang PE. Assessment of case definitions for identifying acute liver injury in large observational databases. *Drug Saf*. 2013 Aug;36(8):651-61.
19. Le HV, Beach KJ, Powell G, Pattishall E, Ryan P, Mera RM. Performance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases. *Stat Methods Med Res*. 2011 Jun 16.
20. Li X, Hui S, Ryan P, Rosenman M, Overhage M. Statistical visualization for assessing performance of methods for safety surveillance using electronic databases. *Pharmacoepidemiol Drug Saf*. 2013 May;22(5):503-9.
21. Madigan D, Ryan P, Simpson S, Zorych I. Bayesian Methods in Pharmacovigilance. In , *Bayesian Statistics 9: Oxford Scholarship Online*; 2011.
22. Madigan D, Ryan PB. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research. *Epidemiology*. 2011 Sep;22(5):629-31.

## REFERENCE LIST

23. Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, et al. Evaluating the impact of database heterogeneity on observational study results. *Am J Epidemiol*. 2013 Aug 15;178(4):645-51.
24. Madigan D, Schuemie MJ, Ryan PB. Empirical Performance of the Case–Control Method: Lessons for Developing a Risk Identification and Analysis System. *Drug Safety*. 2013 2013/10/01;36(1):73-82.
25. Madigan DB, Ryan PB, Schuemie MJ. Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies. *Therapeutic Advances in Drug Safety*. 2013;4(2):53-62.
26. Mittal S, Madigan DB, Burd RS, Suchard MA. High-dimensional, massive sample-size Cox proportional hazards regression for survival analysis. *Biostatistics*. 2013 October 4, 2013.
27. Murray RE, Ryan PB, Reisinger SJ. Design and validation of a data simulation model for longitudinal healthcare data. *AMIA Annual Symposium proceedings / AMIA Symposium AMIA Symposium*. 2011;2011:1176-85.
28. Norén GN, Bergvall T, Ryan P, Juhlin K, Schuemie M, Madigan D. Empirical Performance of the Calibrated Self-Controlled Cohort Analysis Within Temporal Pattern Discovery: Lessons for Developing a Risk Identification and Analysis System. *Drug Safety*. 2013 2013/10/01;36(1):107-21.
29. Noren GN, Hopstadius J, Bate A, Edwards IR. Safety surveillance of longitudinal databases: methodological considerations. *Pharmacoepidemiol Drug Saf*. 2011 Jul;20(7):714-7.
30. Noren GN, Hopstadius J, Bate A, Edwards IR. Safety surveillance of longitudinal databases: results on real-world data. *Pharmacoepidemiol Drug Saf*. 2012 Jun;21(6):673-5.
31. Noren GN, Hopstadius J, Bate A, Kristina Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. *Data Min Knowl Discov*. 2010;20(3):361-87.
32. Ogunyemi OI, Meeker D, Kim HE, Ashish N, Farzaneh S, Boxwala A. Identifying Appropriate Reference Data Models for Comparative Effectiveness Research (CER) Studies Based on Data from Clinical Information Systems. *Med Care*. 2013 Aug;51(8 Suppl 3):S45-52.
33. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. *J Am Med Inform Assoc*. 2012 Jan-Feb;19(1):54-60.

## REFERENCE LIST

34. Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for Evidence Based Epidemiology. *Drug Safety*. 2013 2013/10/01;36(1):5-14.
35. Page D, Santos Costa V, Natarajan S, Barnard A, Peissig P, Caldwell M. Identifying adverse drug events by relational learning. *Proceedings of the Twenty-Sixth AAAI Conference on Artificial Intelligence*; 2012; Toronto; 2012. p. 1599-605.
36. Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. *Journal of Biomedical Informatics*. 2012;45(4):689-96.
37. Reich CG, Ryan PB, Schuemie MJ. Alternative Outcome Definitions and Their Effect on the Performance of Methods for Observational Outcome Studies. *Drug Safety*. 2013 2013/10/01;36(1):181-93.
38. Reich CG, Ryan PB, Suchard MA. The Impact of Drug and Outcome Prevalence on the Feasibility and Performance of Analytical Methods for a Risk Identification and Analysis System. *Drug Safety*. 2013 2013/10/01;36(1):195-204.
39. Reisinger SJ, Ryan PB, O'Hara DJ, Powell GE, Painter JL, Pattishall EN, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. *J Am Med Inform Assoc*. 2010 Nov-Dec;17(6):652-62.
40. Ryan PB. Using Exploratory Visualization in the Analysis of Medical Product Safety in Observational Healthcare Data. In: Krause A, O'Connell M, editors. *A Picture is Worth a Thousand Tables*: Springer US; 2012. p. 391-413.
41. Ryan PB. Statistical challenges in systematic evidence generation through analysis of observational healthcare data networks. *Stat Methods Med Res*. 2013 February 1, 2013;22(1):3-6.
42. Ryan PB, Madigan D, Stang PE, Schuemie MJ, Hripcsak G. Medication-Wide Association Studies. *CPT: pharmacomet syst pharmacol*. 2013;2:e76.
43. Ryan PB, Madigan DB, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. *Statistics in medicine*. 2012 Dec 30;31(30):4401-15.

## REFERENCE LIST

44. Ryan PB, Madigan DB, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Response to comment on 'empirical assessment of methods for risk identification in healthcare data'. *Statistics in medicine*. 2013 Mar 15;32(6):1075-7.
45. Ryan PB, Schuemie MJ. Evaluating Performance of Risk Identification Methods Through a Large-Scale Simulation of Observational Data. *Drug Safety*. 2013 2013/10/01;36(1):171-80.
46. Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical Performance of a New User Cohort Method: Lessons for Developing a Risk Identification and Analysis System. *Drug Safety*. 2013 2013/10/01;36(1):59-72.
47. Ryan PB, Schuemie MJ, Madigan DB. Empirical Performance of a Self-Controlled Cohort Method: Lessons for Developing a Risk Identification and Analysis System. *Drug Safety*. 2013 2013/10/01;36(1):95-106.
48. Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a Reference Set to Support Methodological Research in Drug Safety. *Drug Safety*. 2013 2013/10/01;36(1):33-47.
49. Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A Comparison of the Empirical Performance of Methods for a Risk Identification System. *Drug Safety*. 2013 2013/10/01;36(1):143-58.
50. Ryan PB, Suchard MA, Schuemie MJ, Madigan DB. Learning from Epidemiology: Interpreting Observational Database Studies for the Effects of Medical Products. *Statistics in Biopharmaceutical Research*. 2013;5(3):170-9.
51. Ryan PB, Welebob E, Hartzema AG, Stang PE, Overhage JM. Surveying US Observational Data Sources and Characteristics for Drug Safety Needs. *Pharmaceutical Medicine*. 2010;24(4):231-8
52. Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. *Pharmacoepidemiol Drug Saf*. 2011 Mar;20(3):292-9.
53. Schuemie MJ. Safety surveillance of longitudinal databases: further methodological considerations. *Pharmacoepidemiol Drug Saf*. 2012 Jun;21(6):670-2.
54. Schuemie MJ, Coloma PM, Straatman H, Herings RM, Trifiro G, Matthews JN, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. *Med Care*. 2012 Oct;50(10):890-7.

## REFERENCE LIST

55. Schuemie MJ, Gini R, Coloma PM, Straatman H, Herings RMC, Pedersen L, et al. Replication of the OMOP Experiment in Europe: Evaluating Methods for Risk Identification in Electronic Health Record Databases. *Drug Safety*. 2013 2013/10/01;36(1):159-69.
56. Schuemie MJ, Madigan DB, Ryan PB. Empirical Performance of LGPS and LEOPARD: Lessons for Developing a Risk Identification and Analysis System. *Drug Safety*. 2013 2013/10/01;36(1):133-42.
57. Schuemie MJ, Ryan PB, Dumouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. *Statistics in medicine*. 2013 Jul 30;30(10).
58. Schuemie MJ, Ryan PB, Suchard MA, Shahn Z, Madigan DB. Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature. *Biostatistics*. 2013 Sep 25.
59. Simpson SE, Madigan DB, Zorych I, Schuemie MJ, Ryan PB, Suchard MA. Multiple self-controlled case series for large-scale longitudinal observational databases. *Biometrics*. 2013 Oct 11.
60. Stang PE, Ryan PB, Dusetzina SB, Hartzema AG, Reich C, Overhage JM, et al. Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. *Health Outcomes Research in Medicine*. 2012;3(1):e37-e44.
61. Stang PE, Ryan PB, Overhage JM, Schuemie MJ, Hartzema AG, Welebob E. Variation in Choice of Study Design: Findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) Survey. *Drug Safety*. 2013 2013/10/01;36(1):15-25.
62. Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. *Ann Intern Med*. 2010 Nov 2;153(9):600-6.
63. Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan DB. Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model. *ACM Trans Model Comput Simul*. 2013;23(1):1-17.
64. Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan DB. Empirical Performance of the Self-Controlled Case Series Design: Lessons for Developing a Risk Identification and Analysis System. *Drug Safety*. 2013 2013/10/01;36(1):83-93.

## REFERENCE LIST

65. Trifiro G, Patadia V, Schuemie MJ, Coloma PM, Gini R, Herings R, et al. EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. *Studies in health technology and informatics*. 2011;166:25-30.
66. Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al. An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance. *Drug Safety*. 2013 2013/01/01:1-16.
67. Zorych I, Madigan DB, Ryan PB, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. *Stat Methods Med Res*. 2013 February 1, 2013;22(1):39-56.